TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Complexa raises $13M to fund trials of kidney disease drug

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Wednesday, June 4, 2014, 10:51 a.m.
 

Complexa Inc., a South Side-based drug development company, said it raised $13 million from investors that will fund clinical trials of a drug to treat kidney disease.

The funding round, Complexa's second, was led by Jafco Life Science Investment, an arm of Japanese private equity firm Jafco Co. Ltd.

The company previously raised more than $8 million from venture capital investors to license and develop molecules discovered and patented by professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

There is “great interest” in Complexa's work from large pharmaceutical companies, Jafco officials said in a statement.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.

 

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Pipeline companies weather downturn in prices of natural gas, oil
  2. Super Bowl ads win by playing to viewers’ emotions, experts say
  3. U.S. Steel maps out greater efficiency for 2015
  4. Pennsylvania shale gas producers received hundreds of environmental citations in 4 years, PennEnvironment says
  5. SEC alleges BNY Mellon bribed foreign investors by handing internships to their relatives
  6. Alibaba ripped  in report
  7. ‘Patient’ Fed keeps interest rates flat
  8. McDonald’s replaces CEO amid sales decline, effort to transform image
  9. Super Bowl draws big increase in first-time advertisers
  10. Emergency room visits decline as navigators steer patients to proper medical care
  11. U.S. Steel warns it may lay off almost 2,000 workers in Alabama, Texas